TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck: FDA reviewing tablet to eliminate allergy

About The Tribune-Review
The Tribune-Review can be reached via e-mail or at 412-321-6460.
Contact Us | Video | Photo Reprints

By The Associated Press

Published: Thursday, March 28, 2013, 12:01 a.m.

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.

for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Tesla delivers  1st cars in China
  2. Corbett: Coal is working
  3. Drugmakers ready to carve out deals any way they can
  4. ‘Sweet spot’ mid-cap stocks worthy of investor affection
  5. Record cold facilitates coal’s comeback
  6. PNC’s CEO elected board chairman
  7. ‘Old GM’ defense expected in court fight over faulty ignition switch
  8. AT&T joins crowded field with online video plans
  9. Google challenges nonprofits on ideas to use Glass
  10. McDonald’s profit slips amid weak sales
Subscribe today! Click here for our subscription offers.